跳至主要内容
临床试验/NCT03298204
NCT03298204已完成不适用

A Multicenter Analysis of Definitive (Chemo)Radiotherapy With or Without Chemotherapy for Patients With Esophageal Cancer - 3JECROG-R01

Chinese Academy of Medical Sciences1 个研究点 分布在 1 个国家目标入组 2,762 人开始时间: 2017年6月1日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
2,762
试验地点
1
主要终点
Overall survival

研究概览

简要总结

The aim of this observational study is to retrospectively collect survival data for 3000 primary esophageal cancer patients from multicenter between January 2000 to present. Based on a Cox model, we want to develope a nomogram that predicts local recurrence, distant metastases, and survival for patients treated with radiotherapy or chemoradiotherapy with or without chemotherapy.

研究设计

研究类型
Observational
观察模型
Case Control
时间视角
Retrospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Histologically confirmed squamous cell carcinoma, adenocarcinoma of the esophageal or esophagogastric junction Unresectable or potentially resectable tumor (cT3-4N0-1M0-M1b, without visceral metastasis, according to AJCC 6th) based on standard primary staging by EUS and CT
  • Age>18 years
  • No distant metastasis other than supraclavicular lymph nodes
  • No prior history of thoracic radiation
  • Patients must have normal organ and marrow function as defined below: Leukocytes: greater than or equal to 3,500 G/L; Platelets: greater than or equal to 100,000/mm3 .Hemoglobin:greater than or equal to 10g/L .Total bilirubin: within normal institutional limits; AST/ALT: less than or equal to 1.5 times the upper limit; Creatinine within normal upper limits

排除标准

  • Patients with other cancer history except cervical carcinoma in situ and non-malignant melanoma skin cancer during 5 years before diagnosis of esophageal cancer
  • Pregnant or lactating females
  • Contraindication for radiotherapy or chemotherapy

结局指标

主要结局

Overall survival

时间窗: 2 year

次要结局

  • Progress free survival(2 year)
  • Locoregional recurrence free survival(2 year)
  • Distant metastasis free survival(2 year)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Zefen Xiao

MD

Chinese Academy of Medical Sciences

研究点 (1)

Loading locations...

相似试验